| EVGN Stock | | | ILA 602.20 18.60 3.19% |
CTO
Dr. Hagai Karchi serves as Chief Technology Officer and Head of RD AgBiologicals at Evogene Ltd since January 2018. He is a coFounder of the Company and his work experience includes the following roles Chief Technology Officer and Head of RD Crop Enhancement at the Company, Executive Vice PresidentDevelopment and Chief Technology Officer at the Company and Director of Evogene subsidiary, Evogene Inc, since September 2006 since 2018.
| Age | 56 |
| Tenure | 6 years |
| Phone | (972) 8 946 6724 |
| Web | www.evogene.com |
Karchi holds a BS degree and a MS degree, both in Plant Genetics from The Hebrew University of Jerusalem and a Doctorate of Science degree in Plant Genetics and Genomics, jointly from The Weizmann Institute of Science and The Hebrew University of Jerusalem.
Evogene Management Efficiency
The company has return on total asset
(ROA) of
(0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.
Evogene has accumulated 2.39
M in total debt with debt to equity ratio
(D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Evogene has a current ratio of 12.49, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Evogene until it has trouble settling it off, either with new capital or with free cash flow. So, Evogene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evogene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evogene to invest in growth at high rates of return. When we think about Evogene's use of debt, we should always consider it together with cash and equity.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people. Evogene (EVGN) is traded on Tel Aviv Stock Exchange in Israel and employs 133 people.
Management Performance
Evogene Leadership Team
Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Kapel, Executive Vice President-Technology | |
| Martin Gerstel, Chairman of the Board | |
| Oded Shoseyov, Director | |
| Yaron Eldad, Chief Officer | |
| Eyal Ronen, Exec Devel | |
| Adina Makover, Independent Director | |
| Adrian Percy, Director | |
| Sarit Firon, Independent Director | |
| Sassi Masliah, Exec Devel | |
| Liat Wejgman, VP HR | |
| Eran Kosover, Executive Vice President & General Manager Ag-Chemicals | |
| Ofer CPA, CEO Pres | |
| Ofer Haviv, President, Chief Executive Officer | |
| Ido Dor, Executive Vice President & General Manager Ag-Biologicals | |
| Dotan Borenstein, Chief Ltd | |
| Nir Arbel, Chief Officer | |
| Hagai Karchi, Chief Technology Officer & Head of R&D Ag-Biologicals | |
| Leon Recanati, Independent Director | |
| Alin SelaBrown, Vice President Screening & Validation Systems | |
| Kinneret Savitsky, Independent Director | |
| Eyal Emmanuel, Executive Vice President-R&D | |
| Arnon Heyman, Vice President & General Manager of Ag-Seeds | |
| Alex Taskar, Chief Financial Officer | |
| Ziv Kop, Independent Director | |
| Elran MBA, Chief Ltd | |
Evogene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Information and Resources on Investing in Evogene Stock
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock: Check out
Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
For information on how to trade Evogene Stock refer to our
How to Trade Evogene Stock guide.
You can also try the
Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.